Gilead Invests In Synthetic Biology Partnership For Next Gen CAR-Ts
Adapted Cells Can Sense Tumor Microenvironment
Gilead’s Kite is the current leader in CAR-T, but is looking for ways to stay ahead of competitors and find safer and more effective next-generation therapies.
You may also be interested in...
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.